Patents by Inventor Xavier Jacq

Xavier Jacq has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220033397
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 3, 2022
    Inventors: James Samuel Shane ROUNTREE, Steven Kristopher WHITEHEAD, Adam Piotr TREDER, Lauren Emma PROCTOR, Steven David SHEPHERD, Frank BURKAMP, Joana Rita Castro COSTA, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYCKA, Aaron CRANSTON, Xavier JACQ
  • Publication number: 20220016115
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Inventors: James Samuel Shane ROUNTREE, Peter HEWITT, Mary Melissa MCFARLAND, Frank BURKAMP, Christina BELL, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYKA, Aaron CRANSTON, Xavier JACQ, Lauren PROCTOR
  • Patent number: 10690656
    Abstract: The present application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, the application relates to ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. Further, the use of USP4 inhibitors in the treatment of cancer and methods of screening is described, in particular, use of inhibitors of USP4 in the treatment of tumours defective in double-strand break repair (DSBR) and/or tumours resistant to platinum-based chemotherapy, or to sensitise, i.e. chemosensitise or radiosensitise tumours to other therapeutic agents.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: June 23, 2020
    Assignees: MISSION THERAPEUTICS LIMITED, CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Xavier Jacq, Helen Robinson, Yaara Ofir-Rosenfeld, Stephen Jackson, Paul Wijnhoven, Ryotaro Nishi
  • Patent number: 10527610
    Abstract: The present invention relates to materials and methods for high throughput monitoring of target engagement of isopeptidases, such as deubiquitylating enzymes by, inter alia, small molecule inhibitors. In particular the invention relates to development of high throughput assays to measure isopeptidase activity in biological samples, such as cells, animal tissues, animal tumours, human tissue or patient-derived biopsies.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 7, 2020
    Assignee: Mission Therapeutics Limited
    Inventors: Xavier Jacq, Quentin Gueranger, Jeanine Ann Harrigan
  • Publication number: 20190033292
    Abstract: The present application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, the application relates to ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. Further, the use of USP4 inhibitors in the treatment of cancer and methods of screening is described, in particular, use of inhibitors of USP4 in the treatment of tumours defective in double-strand break repair (DSBR) and/or tumours resistant to platinum-based chemotherapy, or to sensitise, i.e. chemosensitise or radiosensitise tumours to other therapeutic agents.
    Type: Application
    Filed: February 29, 2016
    Publication date: January 31, 2019
    Inventors: Xavier JACQ, Helen ROBINSON, Yaara OFIR-ROSENFELD, Stephen JACKSON, Paul WIJNHOVEN, Ryotaro NISHI
  • Publication number: 20170122935
    Abstract: The present invention relates to materials and methods for high throughput monitoring of target engagement of isopeptidases, such as deubiquitylating enzymes by, inter alia, small molecule inhibitors. In particular the invention relates to development of high throughput assays to measure isopeptidase activity in biological samples, such as cells, animal tissues, animal tumours, human tissue or patient-derived biopsies.
    Type: Application
    Filed: June 15, 2015
    Publication date: May 4, 2017
    Inventors: Xavier JACQ, Quentin GUERANGER, Jeanine Ann HARRIGAN
  • Patent number: 8648076
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: February 11, 2014
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Stefania Vallese, Matteo Colombo
  • Patent number: 7875613
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: January 25, 2011
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Xavier Jacq, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • Publication number: 20100048575
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use: Formula (I) wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1
    Type: Application
    Filed: October 25, 2007
    Publication date: February 25, 2010
    Inventors: Philippe Guedat, Xavier Jacq, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • Publication number: 20090215786
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: July 26, 2006
    Publication date: August 27, 2009
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Stefania Vallese, Matteo Colombo
  • Publication number: 20090181972
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: December 5, 2006
    Publication date: July 16, 2009
    Inventors: Philippe Guedat, Guillaune Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Ilaria Peretto, Stefano Vignando
  • Patent number: 7462615
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: December 9, 2008
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Ilaria Peretto, Stefano Vignando
  • Publication number: 20080103149
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1
    Type: Application
    Filed: October 30, 2006
    Publication date: May 1, 2008
    Inventors: Philippe GUEDAT, Xavier Jacq, Frederic Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • Publication number: 20070166778
    Abstract: The invention relates to substrates and methods suitable for assaying deubiquitinating enzyme activity, and in particular for screening inhibitors of enzymes involved in removal of mono or poly-ubiquitin chains from a target protein as well as inhibitors of ubiquitin precursors. Such inhibitors may have utility in the treatment of disease states associated with ubiquitin processing as well as proteolysis.
    Type: Application
    Filed: January 12, 2007
    Publication date: July 19, 2007
    Inventors: Xavier Jacq, Jean-Christophe Rain
  • Publication number: 20070135439
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: December 8, 2005
    Publication date: June 14, 2007
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, IIaria Peretto, Stefano Vignando
  • Publication number: 20070032499
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: August 5, 2005
    Publication date: February 8, 2007
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rerni Delansorne, Stefania Vallese, Matteo Colombo